IN8bio Q2 FY26 net loss narrows to $4.8 million; cash falls to $18 million
Reuters2026/08/06 20:09- IN8bio posted a Q2 net loss of $4.8 million, narrowing from $5.1 million a year earlier; loss per share improved to $0.25 from $1.24.
- R&D expense was flat at $2.5 million; G&A expense fell 10% to $2.4 million.
- Cash totaled $18 million at June 30, 2026, down from $27.09 million at Dec. 31, 2025.
- ASCO 2026 update showed DeltEx DRI repeat dosing in newly diagnosed GBM with mOS above 19.5 months, mPFS of 13 months; 43% alive at 24 months.
- Management said INB-619 advanced into IND-enabling studies; initial in vivo preclinical data remains targeted for H2 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
